Minimal Residual Disease Testing Market Size To Surpass USD 5.74 Billion By 2032 Driven By Advances In Precision Oncology And Early Relapse Detection SNS Insider

(MENAFN- GlobeNewsWire - Nasdaq) According to SNS Insider, U.S. Minimal Residual Disease Testing Market Poised to Hit USD 1.58 Billion by 2032 Amid Rising Adoption of Next-Generation Sequencing (NGS) and Personalized Treatment Strategies.

Austin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Minimal Residual Disease Testing Market Size & Growth Analysis:

According to the latest analysis by SNS Insider, the Minimal Residual Disease Testing Market was valued at USD 2.16 billion in 2023 and is projected to reach USD 5.74 billion by 2032, registering a CAGR of 11.50% over the forecast period of 2024–2032. In the United States, the market stood at USD 0.65 billion in 2023 and is forecasted to grow to USD 1.58 billion by 2032 at a CAGR of 10.38%. This growth is fueled by heightened demand for precision oncology tools, expanding clinical validation of MRD assays, and the integration of NGS technologies into hematologic cancer management.

Get Free Sample Report of the Minimal Residual Disease Testing Market:

Minimal Residual Disease Testing Market Overview

Minimal Residual Disease testing plays a critical role in oncology and hematology by detecting microscopic levels of cancer cells post-treatment, offering a predictive edge for relapse and treatment planning. The rapid evolution of molecular diagnostics and liquid biopsy platforms is enabling earlier intervention, better patient stratification, and improved survival outcomes. The market is witnessing significant investment from diagnostic companies, research institutions, and pharmaceutical firms aiming to enhance MRD detection sensitivity and expand clinical applications.

Major Players Analysis Listed in this Report are:

• Exact Sciences Corporation – Oncotype MAP
• GRAIL, LLC – Galleri (Developing MRD applications)
• Veracyte, Inc.
• Natera, Inc. – Signatera
• Guardant Health – Guardant Reveal
• F. Hoffmann-La Roche Ltd – AVENIO Tumor Tissue Analysis (Exploring MRD applications)
• FOUNDATION MEDICINE, INC. – FoundationOne Tracker
• QIAGEN – ipsogen MRD Tests
• mdxhealth
• Bio-Techne – Asuragen QuantideX qPCR Assays

Minimal Residual Disease Testing Market Report Scope

Report Attributes	Details
Market Size in 2023	US$ 2.16 billion
Market Size by 2032	US$ 5.74 billion
CAGR	CAGR of 11.50% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Regional Analysis	North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)

Minimal Residual Disease Testing Market Segment Analysis

By Technology:

Flow cytometry was the largest MRD testing segment in 2023, occupying more than 40% of the market share globally. Its popularity is related to its high-throughput, low cost, and wide presence in hospital labs. Flow cytometry is a fast measurement of residual tumor cells and is widely used in laboratories and hospitals.

The fastest growing segment is next-generation sequencing (NGS), which provides ultra-high sensitivity and precision. NGS is capable of identifying one cancer cell in a million normal cells, which has an enormous advantage for deep sequencing in MRD determination.

By Cancer Type:

Hematological malignancies are projected to hold the largest share in the MRD testing Market through 2023, accounting for over half of all shares. That supremacy is based on the crucial role MRD plays in watching remission and relapse for blood cancers, which have clearer molecular targets as well as tests.

By Business Type:

The hospitals and specialty clinics were the dominant sector in 2023, with a share of 45 % of the overall market. These environments have the facilities, well-trained staff, and volume-based need for doing complex diagnostics such as MRD.

Diagnostic laboratories are the largest and fastest-growing end-user segment, based on increasing outsourcing activities like the enhancement of in-house molecular diagnostic capabilities & decentralizing testing services.

For a Personalized Briefing with Our Industry Analysts, Connect Now:

Minimal Residual Disease Testing Market Segmentation

By Technology

• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-generation sequencing (NGS)
• Others

By Cancer Type

• Haematological Malignancy
  • Leukaemia
  • Lymphoma
• Solid Tumours

By Business

• Hospitals and Speciality Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Others

Regional Insights

Among regions, North America accounted for the largest share of the MRD Testing Market in 2023(39.9% global market). The area is also advantaged by a strong hold of precision diagnostics with early adoption, presence of major players such as Adaptive Biotechnologies and Invivoscribe, and state-of-the-art clinical research facilities. The U.S., in particular, leads the region due to its significant load of hematologic malignancies and by adopting MRD into national oncology care standards.

Asia-Pacific is the largest growing region, and will continue to show significant growth through 2032. Increased incidence of cancer, expanding access to healthcare, growing investment in clinical genomics, and government initiatives such as driving growth. China has become dominant in the region with strategic alliances involving Western diagnostic companies and rapid buildout of oncology research centers and lab capacity.

Recent Developments (Minimal Residual Disease Testing Market)

• June 2024 – Adaptive Biotechnologies received an FDA Breakthrough Device Designation for their clonoSEQ MRD test to monitor HFF patients with multiple myeloma in blood, revolutionizing the procedure of non-invasive testing.
• May 2024 – Invivoscribe issued another kit for standardized MRD testing of FLT3 mutations, this one available in flow cytometric and NGS platforms to enhance AML diagnosis.

Buy the Full Minimal Residual Disease Testing Market Report (Single-User License) Now:

Suggested Unique USP Sections for Client Proposal

Regulatory Landscape and Policy Mapping by Country – Comparative analysis of MRD testing approvals, reimbursement frameworks, and integration into clinical practice guidelines.

Clinical Trial Integration and Pipeline Dependency Mapping – Tracks how biopharma companies are incorporating MRD as surrogate endpoints in Phase II/III oncology trials.

Liquid Biopsy Convergence Landscape – Insights on how MRD testing is intersecting with liquid biopsy innovations across oncology subtypes.

Diagnostic Pathway Optimization Models – Visual maps and analytics showing MRD integration points in patient care pathways for specific cancers.

Health Economics & Budget Impact Models (BIM) – Cost-saving simulations for MRD-based care vs traditional relapse detection across healthcare systems.

Lab Infrastructure and Readiness Index (Global) – Scoring model evaluating country-level readiness to adopt MRD testing (based on molecular lab density, accreditation, skilled personnel, etc.).

MRD Sensitivity vs. Clinical Outcome Meta-analysis – Quantitative review linking detection thresholds with relapse prediction and overall survival benefits.

Access Complete Report Details of Minimal Residual Disease Testing Market Analysis & Outlook@

[For more information or need any customization research mail us at ...]

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: ...

MENAFN11082025004107003653ID1109912142